These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29193649)

  • 1. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol.
    Rotter A; de Oliveira ZNP
    J Dtsch Dermatol Ges; 2017 Dec; 15(12):1185-1190. PubMed ID: 29193649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease.
    Taran K; Wnęk A; Kobos J; Andrzejewska E; Przewratil P
    Immunobiology; 2017 Nov; 222(11):1035-1042. PubMed ID: 28601470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.
    Storch CH; Hoeger PH
    Br J Dermatol; 2010 Aug; 163(2):269-74. PubMed ID: 20456345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
    Pan WK; Li P; Guo ZT; Huang Q; Gao Y
    Pediatr Blood Cancer; 2015 Aug; 62(8):1414-20. PubMed ID: 25728347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Infantile hemangioma and propranolol: a therapeutic "revolution". Literature review].
    Yilmaz L; Dangoisse C; Semaille P
    Rev Med Brux; 2013; 34(6):479-84. PubMed ID: 24505868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?
    Babiak-Choroszczak L; Giżewska-Kacprzak K; Gawrych E; Fischer K; Walecka A; Puchalska-Niedbał L; Rajewska-Majchrzak J; Bagłaj M
    Adv Clin Exp Med; 2018 May; 27(5):703-710. PubMed ID: 29790692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the mechanisms of angiogenesis in infantile hemangioma.
    Xiang S; Gong X; Qiu T; Zhou J; Yang K; Lan Y; Zhang Z; Ji Y
    Biomed Pharmacother; 2024 Sep; 178():117181. PubMed ID: 39059349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
    Makkeyah SM; Elseedawy ME; Abdel-Kader HM; Mokhtar GM; Ragab IA
    Pediatr Hematol Oncol; 2022 Apr; 39(3):215-224. PubMed ID: 34477031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial.
    Zaher H; Rasheed H; El-Komy MM; Hegazy RA; Gawdat HI; Abdel Halim DM; Abdel Hay RM; Hegazy RA; Mohy AM
    J Am Acad Dermatol; 2016 Mar; 74(3):499-505. PubMed ID: 26685718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.
    Thaivalappil S; Bauman N; Saieg A; Movius E; Brown KJ; Preciado D
    JAMA Otolaryngol Head Neck Surg; 2013 Oct; 139(10):1026-31. PubMed ID: 24135743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma].
    Yuan WL; Wang XK
    Shanghai Kou Qiang Yi Xue; 2022 Aug; 31(4):400-405. PubMed ID: 36710554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
    Sagi L; Zvulunov A; Lapidoth M; Ben Amitai D
    Dermatology; 2014; 228(2):136-44. PubMed ID: 24556822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment.
    Li L; Yu L; Xu Z; Wei L; Zhang B; Han X; Sun Y; Ma L
    J Cosmet Dermatol; 2023 Dec; 22(12):3369-3374. PubMed ID: 37313653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.
    Kim LHC; Hogeling M; Wargon O; Jiwane A; Adams S
    J Pediatr Surg; 2011 Apr; 46(4):759-763. PubMed ID: 21496551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Infantile haemangioma: an update].
    Reimer A; Ott H
    Hautarzt; 2019 Jun; 70(6):447-458. PubMed ID: 31101924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.
    Przewratil P; Kobos J; Wnęk A; Szemraj J; Wyrzykowski D; Chrzanowska B; Andrzejewska E; Taran K
    Immunol Lett; 2016 Jul; 175():44-9. PubMed ID: 27178307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The advance of β-blockers in the treatment of infantile hemangiomas].
    Lin TT; He YJ
    Zhonghua Yan Ke Za Zhi; 2013 Dec; 49(12):1138-44. PubMed ID: 24499701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Propranolol in infantile hemangiomas].
    Léauté-Labrèze C
    Arch Pediatr; 2015 Apr; 22(4):452-5. PubMed ID: 25753275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of propanolol for treatment of infantile haemangioma.
    Andersen IG; Rechnitzer C; Charabi B
    Dan Med J; 2014 Feb; 61(2):A4776. PubMed ID: 24495884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol].
    Zhao ZF; Lü RR; Huo R; Fu HB; Xu GQ
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2011 Sep; 27(5):359-61. PubMed ID: 22259987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.